Navigation Links
Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
Date:6/16/2008

BOSTON, June 16 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VOQP), entitled, "Robust Pipeline of Niche' Cancer Therapies with Billion Dollar Upside."

This review is available at website: http://www.scimitarequity.com.

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimita
'/>"/>

SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
2. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
3. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
4. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp.
7. Lorus initiates development program exploring novel route of administration for LOR-2040
8. SemBioSys initiates toxicology study for safflower-produced insulin
9. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
10. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... the National Institute of Standards and Technology (NIST) and ... to introduce magnetic impurities in a semiconductor crystal by ... in a recent paper,* this technique will enable researchers ... a time to learn about its electrical and magnetic ...
(Date:12/4/2009)... Dec. 4 Stemline Therapeutics, Inc. today announced that data ... SL-501, in both in vitro and animal models ... poster presentation at the upcoming 51st Annual Meeting of the ... Orleans from December 5-8, 2009. The poster will be presented ...
(Date:12/3/2009)... MELVILLE, N.Y., Dec. 3 Nikon Corporation, an ... it has signed a licensing agreement with Harvard ... Stochastic Optical Reconstruction Microscopy (STORM) technology. Under the ... enabled microscopy systems and market them with the ...
(Date:12/3/2009)... PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: ... announced a voluntary recall of five lots and voluntary ... (ADHD) patch Daytrana ® . Shire is taking this ... in the future may not meet their release liner ...
Breaking Biology Technology:NIST researchers put a new spin on atomic musical chairs 2Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5
... platform, company develops first orally-administered vaccine to ... -, SAN FRANCISCO, Oct. 24 Vaxart ... oral vaccines, today announced,positive efficacy results from preclinical ... Tucker, PhD, Vaxart founder and vice president of,research, ...
... October, 2008, Stenum Hospital, Germany, just five years after Jim Rider, ... has now surpassed the 600 American patient milestone. , ... ... healthcare crisis in the US getting worse, and the knowledge that ...
... Oct. 23 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... Diego on Tuesday, October 28, 2008 at 10:30 a.m. ... and Chief Financial Officer, will,be providing a corporate overview., ... a recording will be made,available following the event. The ...
Other Biology Technology:Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies 2Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies 3Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies 4Stenum Hospital Does its 600th American Disc Replacement Surgery 2
(Date:12/4/2009)... to an analysis of statewide data taken from 1998-2001, ... year were more than three times likely to report ... their insurance status during pregnancy and delivery. , ... times more likely among mothers with Medicaid coverage, and ...
(Date:12/4/2009)... cells, University of Iowa investigators have shown how activation ... disrupts the electrical activity of heart cells. ... published online Dec. 3 in the journal PLoS ... great interest in calmodulin kinase II as a critical ...
(Date:12/3/2009)... plant and animal species can be likened to emptying a ... potential medicines into the trash, or replacing every local cuisine ... their habitats may not just make the world boring. New ... risk for catching some nasty disease. , "Habitat destruction and ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2U-Iowa study helps advance heart-related research 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Kashi Company Introduces TLC 28R 29 Dark Mocha Almond Chewy Bar 52224 1Kashi Company Introduces TLC 28R 29 Dark Mocha Almond Chewy Bar 52224 2Novasys Medical Receives 2418 95 Million in Second Tranche of Series D Financing 52219 1Novasys Medical Receives 2418 95 Million in Second Tranche of Series D Financing 52219 2The Neutraceutical Company Announces Powerful New Feel Good Product 52215 1The Neutraceutical Company Announces Powerful New Feel Good Product 52215 2
... Zakouma National Park, the last stronghold for the savanna ... about 1,000 animals, down from an estimated 3,000 in ... elephant populations particularly when herds venture seasonally outside ... exceedingly difficult in Chad. Several park guards have ...
... new research shows size isn,t always an advantage in ... is better. , Michael Kasumovic, a former University ... spiders to determine whether the larger ones had an ... Surprisingly, Kasumovic found the large spiders didn,t always have ...
... --The U.S. Environmental Protection Agency and U.S. Department of ... (NCII) to learn more about the effectiveness of actions ... basin and into the northern Gulf of Mexico, says ... The report also advises how to move forward on ...
Other Biology News:Missing: 2,000 elephants 2EPA and USDA should create new initiative to better monitor nutrients 2EPA and USDA should create new initiative to better monitor nutrients 3EPA and USDA should create new initiative to better monitor nutrients 4
... P20 and Sartolab P20 plus,for Reliable Sterile ... which, attached to a,membrane pump or tube ... 5 liter of media,and aqueous solutions. ... cm2) and an automatic de-aeration,ensures high flow ...
... allows for rapid, convenient, and efficient Denatured ... process utilizes a spin column to make ... concentration of proteins which were electro-eluted in ... ion exchangers, offering high binding capacity fo ...
... III variable angle system, 220-240 V, is used ... Mb DNA fragments by pulsed field gel electrophoresis ... module, variable-speed pump, 14 x 13 cm casting ... 1.5 mm thick comb, screened cap, disposable plug ...
... designed to knockout or alter genes on the ... week. Red/ET recombination allows the exchange of genetic ... faithful manner. An FRT-flanked kanamycin resistance marker cassette ... used to replace a gene on the ...
Biology Products: